Compare RGCO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | EDIT |
|---|---|---|
| Founded | 1912 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 206.0M |
| IPO Year | 2005 | 2016 |
| Metric | RGCO | EDIT |
|---|---|---|
| Price | $22.74 | $2.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 8.2K | ★ 1.4M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 11.21 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $95,334,212.00 | $31,937,000.00 |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $3.36 | N/A |
| P/E Ratio | $47.96 | ★ N/A |
| Revenue Growth | 12.63 | ★ 132.64 |
| 52 Week Low | $19.68 | $0.91 |
| 52 Week High | $23.82 | $4.54 |
| Indicator | RGCO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 59.89 |
| Support Level | $20.49 | $2.01 |
| Resistance Level | $23.01 | $2.36 |
| Average True Range (ATR) | 0.57 | 0.18 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 92.89 | 80.01 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.